Valence Discovery is a technology company.
Valence Discovery has raised $9.0M across 2 funding rounds.
Valence Discovery has raised $9.0M in total across 2 funding rounds.
Valence Discovery has raised $9.0M in total across 2 funding rounds.
Valence Discovery's investors include Acrew Capital, AirAngels, Air Street Capital, Amplify Partners, Downing Ventures, Fifty Years, Kearny Jackson, NextView Ventures, Parkwalk Advisors, Preston-Werner Ventures, Silicon Valley Connect, Adam Lisagor.
Valence Discovery is an AI-driven drug discovery company that builds a machine learning platform for molecular design and optimization, enabling drug discovery teams to leverage deep learning for faster, cheaper, and more innovative therapeutic development.[1][2][3][4] Formerly known as InVivo AI, it serves pharmaceutical companies, contract research organizations like Charles River Labs, and academic labs by addressing challenges in sparse biomedical datasets to design high-quality drug candidates optimized for potency, selectivity, safety, and DMPK parameters.[3][4] The platform democratizes AI access, powering growth through partnerships like Servier and infrastructure on Google Cloud, which has reduced costs and accelerated R&D.[3][4]
Valence Discovery originated as a PhD biotech project at Mila, the world's largest deep learning research institute in Montreal, where the founding team developed deep learning tools for drug discovery during their studies.[2][3][4] Founded in 2018 by CEO and Co-Founder Daniel Cohen, the company rebranded from InVivo AI and is now a Recursion company, evolving from academic research to a commercial platform.[1][4] Early traction came from building AI tools adapted for incomplete biomedical data, leading to scalable deployment on Google Cloud and partnerships that shifted focus to empowering diverse R&D organizations.[3]
Valence rides the wave of AI democratization in drug discovery, where deep learning tackles historically undruggable targets amid rising computational power and data generation advances.[3][4][5] Timing aligns with industry shifts toward AI-optimized candidates, with CEO Daniel Cohen predicting that by 2030, most clinical drugs will involve AI input, fueled by market forces like high R&D costs and the need for novel therapies.[4] It influences the ecosystem by partnering across scales—from academics to big pharma like Servier—accelerating access to advanced tools and fostering virtual cell models for simulating patient responses.[3][4][5]
Valence is poised to expand as a Recursion-powered engine, advancing virtual cells and models like TxPert for out-of-distribution predictions in biology.[5] Trends in agentic AI systems, quantum mechanics datasets, and scalable cloud compute will shape its path, potentially dominating AI-driven small molecule design.[5][6] Its influence may evolve from tool provider to ecosystem leader, enabling broader shifts to AI-native drug pipelines and unlocking unprecedented therapeutic spaces—reinforcing its mission to empower every drug team from day one.[1][4]
Valence Discovery has raised $9.0M across 2 funding rounds. Most recently, it raised $7.0M Seed in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $7.0M Seed | Acrew Capital, AirAngels, Air Street Capital, Amplify Partners, Downing Ventures, Fifty Years, Kearny Jackson, NextView Ventures, Parkwalk Advisors, Preston-Werner Ventures, Silicon Valley Connect, Adam Lisagor, Andrew Berman, Chris Schaepe | |
| Apr 1, 2019 | $2.0M Seed | BoxOne Ventures |